The RAGE/multiligand axis: a new actor in tumor biology

Biosci Rep. 2022 Jul 29;42(7):BSR20220395. doi: 10.1042/BSR20220395.

Abstract

The receptor for advanced glycation end-products (RAGE) is a multiligand binding and single-pass transmembrane protein which actively participates in several chronic inflammation-related diseases. RAGE, in addition to AGEs, has a wide repertoire of ligands, including several damage-associated molecular pattern molecules or alarmins such as HMGB1 and members of the S100 family proteins. Over the last years, a large and compelling body of evidence has revealed the active participation of the RAGE axis in tumor biology based on its active involvement in several crucial mechanisms involved in tumor growth, immune evasion, dissemination, as well as by sculpturing of the tumor microenvironment as a tumor-supportive niche. In the present review, we will detail the consequences of the RAGE axis activation to fuel essential mechanisms to guarantee tumor growth and spreading.

Keywords: advanced glycation; alarmins; receptor advanced glycation end-products; tumor biology; tumor microenvironment.

Publication types

  • Review

MeSH terms

  • Biology
  • Glycation End Products, Advanced* / metabolism
  • Humans
  • Neoplasms* / metabolism
  • Receptor for Advanced Glycation End Products / genetics
  • Receptor for Advanced Glycation End Products / metabolism
  • Receptors, Immunologic
  • S100 Proteins
  • Tumor Microenvironment

Substances

  • Glycation End Products, Advanced
  • Receptor for Advanced Glycation End Products
  • Receptors, Immunologic
  • S100 Proteins